Clinical outcomes of patients receiving three versus four doses of methotrexate with concomitant antithymocyte globulin in match unrelated donor allogeneic stem cell transplant: A single‐center experience
Kittika Poonsombudlert(University of Iowa Health Care), Margarida Magalhaes‐Silverman(University of Iowa Hospitals and Clinics), Sarah L. Mott(University of Iowa), Hira Shaikh(University of Iowa Hospitals and Clinics), Jonathan Lochner(University of Iowa Hospitals and Clinics), Christopher Strouse(University of Iowa Hospitals and Clinics), Umar Farooq(Wake Forest University), Ratdanai Yodsuwan(University of Iowa Health Care)
Cited by 1
Related Papers
Axicabtagene Ciloleucel CAR T-Cell Therapy in Refractory Large B-Cell Lymphoma
|New England Journal of Medicine|2017|6k
Long-term safety and activity of axicabtagene ciloleucel in refractory large B-cell lymphoma (ZUMA-1): a single-arm, multicentre, phase 1–2 trial
|The Lancet Oncology|2018|2.3k
Axicabtagene Ciloleucel as Second-Line Therapy for Large B-Cell Lymphoma
|New England Journal of Medicine|2021|1.6k
Survival with Axicabtagene Ciloleucel in Large B-Cell Lymphoma
|New England Journal of Medicine|2023|437
Sarcopenia is an independent predictor of complications following pancreatectomy for adenocarcinoma
|Journal of Surgical Oncology|2014|274